Adjuvant Therapy for Melanoma.

In recent years, effective systemic therapies have emerged for patients with metastatic melanoma. These therapies have also made their way to the perioperative setting, demonstrating improved recurrence-free survival for subsets of individuals with stage III and IV disease that received therapy after having undergone surgical resection. While adjuvant therapy is recommended for certain patients with stage II, III, and IV disease, patient selection can be nuanced. Adjuvant therapies are not without their own risks, and an individual's ability to tolerate treatment must be weighed. We review key adjuvant therapy trials, recommendations for its use in contemporary practice, and future directions.

Duke Scholars

Author Georgia Marie Beasley Surgical Oncology

Author Kristen Rhodin